For the functional experiments, the anti-tumor potential of MAGE-A3 immunizations was evaluated in a prophylactic setting with non-tumor-bearing mice rather than a therapeutic setting in order to more closely mimic the clinical situation of adjuvant treatment for cancer patients. The gene discussed is MAGEA3; the disease is cancer.